Renerve (ASX:RNV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Renerve (ASX:RNV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - RNV
Proposed issue of securities - RNV
ReNerve Secures up to A$5 Million Funding Facility
ReNerve secures up to A$5 million convertible note facility to fund growth and commercialisation
ReNerve Secures Marketing Approval in Indonesia
ReNerve gains marketing approval for NervAlign® Nerve Cuff in Indonesia, expanding Asia-Pacific footprint
Notification of cessation of securities - RNV
Clarification of Key Terms STC Distribution Agreement
ReNerve appoints J4 as second Empliq manufacturing partner
ReNerve appoints J4 as second Empliq manufacturing partner to scale production amid rising demand
ReNerve appoints distribution partner for Malaysian Market
ReNerve appoints UG Medical as Malaysian distributor for NervAlign products
New distribution agreement for broader Hong Kong market
ReNerve inks exclusive 3-year distribution deal with STC for Greater Bay Area market
Quarterly Investor Presentation
ReNerve reports 79% sales growth, expands US distribution, advances regulatory approvals and clinical validation
Quarterly Investor Webinar
Notification of cessation of securities - RNV
Final Director's Interest Notice - D Rhodes
Q3 FY26 Activities Report and Appendix 4C
ReNerve reports 79% sales growth, regulatory approvals in Asia, and advances nerve repair product development
Nerve Guide Matrix Enters Stage 3 of Commercial Development
ReNerve's NervAlign Nerve Guide Matrix Advances to Stage 3 Commercial Development Ahead of FDA Submission
